On May 30, 2017, Chembio Diagnostics, Inc. (“Chembio”) announced that John J. Sperzel III, the Chief Executive Officer of the Company, is taking a medical leave of absence. In connection with Mr. Sperzel’s leave of absence, on May 30, 2017, the Chembio Board of Directors appointed Sharon Klugewicz, the Company’s President Americas Region, and former Chief Operating Officer, as acting Chief Executive Officer.

Ms. Klugewicz, 49, joined Chembio in 2012. She served as President Americas Region beginning in 2016, after having served as Chief Operating Officer and as Vice President Of QA/QC. Prior to joining Chembio, Ms. Klugewicz served at Pall Corporation (NYSE: PLL) as Senior Vice President, Scientific & Laboratory Services, as well as other prior commercial and operational leadership positions in her 20-year tenure with Pall Corporation.

Chembio’s experienced Executive Leadership Team also includes, Javan Esfandiari, Chief Science And Technology Officer and Executive Vice President, who has been with Chembio since 2000; Richard J. Larkin, Chief Financial Officer and Executive Vice President, who has been with Chembio since 2004; Robert Passas Ph.D., President EMEA and APAC Regions, who joined Chembio in 2016; Tom Ippolito, Vice President Of Regulatory Affairs, QA And QC, who has been with Chembio since 2005; Paul Lambotte, Vice President Product Development, who joined Chembio in 2014; and David Gyorke, Vice President Operations, who joined Chembio last January.

About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Recent Trading Information

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) closed its last trading session down -0.05 at 6.75 with 21,926 shares trading hands.